Agora hosts high-dimensional human transcriptomic, proteomic, and metabolomic evidence for whether or not genes are associated with Alzheimer’s disease (AD). Agora also contains a list of over 600 nascent drug targets for AD that were nominated by AD researchers. The list of nominated targets was contributed by researchers from the National Institute on Aging’s Accelerating Medicines Partnership in Alzheimer’s Disease (AMP-AD) consortium and Target Enablement to Accelerate Therapy Development for Alzheimer’s Disease TREAT-AD centers, as well as other research teams. Other evidence presented in Agora was either generated by AMP-AD and TREAT-AD research teams, or is aggregated from publicly available data sources.
Agora is funded by the National Institute on Aging. It is developed and maintained by Sage Bionetworks.